Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
758.230.11%
QQQ
705.250.1%
BTC/USD
75480.720.1369%
DIA
521.800.11%
GLD
392.630.39%
TLT
80.810.12%

ProMIS Neurosciences Inc

PMNNASDAQ
Trade with Public
Trade with Public
$12.89
-0.37-2.79%
At close: Sep 15, 5:00 PM EST
$14.00
1.118.61%
After Hours: Sep 9, 9:00 AM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareStock Report

ProMIS Neurosciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for ProMIS Neurosciences (PMN).

Price Target Range — 7 Quarters

Analyst Consensus — 7 Analysts

7Buy
Consensus RatingBuy# Analysts7Avg. Consensus PT$73Upside to Avg. PT+424.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 14, 2026GuggenheimYatin SunejaPT RaiseBuy$69→$100
Jul 29, 2026GuggenheimEddie HickmanPT RaiseBuy$35→$69
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Guggenheim Maintains Buy on ProMIS Neurosciences, Raises Price Target to $100

Guggenheim analyst Yatin Suneja maintains ProMIS Neurosciences (NASDAQ:PMN) with a Buy and raises the price target from $69 to $100.
Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on ProMIS Neurosciences, Raises Price Target to $69

Guggenheim analyst Eddie Hickman maintains ProMIS Neurosciences (NASDAQ:PMN) with a Buy and raises the price target from $35 to $69.
Benzinga Newsdesk

PRO
Chardan Capital Maintains Buy on ProMIS Neurosciences, Raises Price Target to $33

Chardan Capital analyst Keay Nakae maintains ProMIS Neurosciences (NASDAQ:PMN) with a Buy and raises the price target from $20 to $33.
Benzinga Newsdesk

PRO
Chardan Capital Initiates Coverage On ProMIS Neurosciences with Buy Rating, Announces Price Target of $20

Chardan Capital analyst Keay Nakae initiates coverage on ProMIS Neurosciences (NASDAQ:PMN) with a Buy rating and announces Price Target of $20.
Benzinga Newsdesk

PRO
Roth Capital Initiates Coverage On ProMIS Neurosciences with Buy Rating, Announces Price Target of $19

Roth Capital analyst Boobalan Pachaiyappan initiates coverage on ProMIS Neurosciences (NASDAQ:PMN) with a Buy rating and announces Price Target of $19.
Benzinga Newsdesk

PRO
Cantor Fitzgerald Initiates Coverage On ProMIS Neurosciences with Overweight Rating

Cantor Fitzgerald analyst Pete Stavropoulos initiates coverage on ProMIS Neurosciences (NASDAQ:PMN) with a Overweight rating.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved